Avinash C Seth

US Patent:

20210299173, Sep 30, 2021

Filed:

Mar 26, 2020

Appl. No.:

16/831244

Inventors:

Avinash Seth - Pomona CA, US
Nikko Lowe - City of Industry CA, US
Robert D. Fish - Irvine CA, US

International Classification:

A61K 35/17
C12N 5/074
C12N 5/0783
C12N 5/0789
C12N 5/0775
A61K 35/545
A61P 35/00

Abstract:

A composition and a method for generating clinically safe NK cells derived from non-fully differentiated stem cells are provided. The non-fully differentiated stem cells are co-cultured with endogenous NK cells isolated from adipocyte-containing tissue to generate a high percentage of clinically safe NK cells, where anti-tumor activity of the clinically safe NK cells in vitro is similar to that of endogenous NK cells. Optimized Production of the clinically safe autologous NK cells from stem cells provides platform for treating cancer patients by applying an effective adoptive immunotherapy ranging from the early to terminal stages.

US Patent:

20200352215, Nov 12, 2020

Filed:

May 7, 2020

Appl. No.:

16/868830

Inventors:

Avinash Seth - Pomona CA, US

International Classification:

A24B 15/30
A61K 36/23
A61K 36/31
A61K 31/26
A61K 38/47
A61K 31/122
A61K 31/375
A61K 31/05
A24B 15/40
A24B 15/28

Abstract:

A tobacco product reduces or mitigates some of the negative effects of tobacco consumption, particularly cancer development. The tobacco product contains (a) nicotine, (b) at least one of an isothiocyanate or isothiocyanate precursor, (c) myrosinase and (d) a synthetic isothiocyanate. The product can further include at least one of thymoquinone, resveratrol, synthetic vitamin C, thymoquinone resveratrol and a synthetic vitamin C.

US Patent:

20190298684, Oct 3, 2019

Filed:

Mar 25, 2019

Appl. No.:

16/363800

Inventors:

- San Dimas CA, US
Avinash Seth - Pomona CA, US

International Classification:

A61K 31/352
A61K 36/28
A61K 31/4745
A61K 31/357
A61K 9/20
A61P 25/28
A61P 1/16

Abstract:

A composition for reducing or mitigating negative effects of alcohol consumption is provided, comprising a source of Dihydromycetin (DHM), a source of a milk thistle extract, and a source of Pyrroloquinoline quinone (PQQ). The source of each DHM and PQQ has at least 95 wt % of the compound. The source of the milk thistle extract has at least 60 wt % silymarin and at least 10 wt % of silybin. The composition is formulated in an orally administrable form consisting of a tablet, a capsule, and an aerosol form. The orally administrable form comprises 10-60 wt % of the DHM, 10-45 wt % of the milk thistle extract, and 0.5-10 wt % of the PQQ in the presence of at least 10 wt % of binder.

US Patent:

20190062711, Feb 28, 2019

Filed:

Jul 24, 2018

Appl. No.:

16/044142

Inventors:

- San Dimas CA, US
Avinash Seth - Pomona CA, US

International Classification:

C12N 5/074
C07K 5/00

Abstract:

The present invention provides compositions and methods for inducing pluripotency in non-embryonic and/or somatic cells using exogenous Tb4, exogenous Sox2, and exogenous Oct4. Induced pluripotent stem cells can be can be simian or murine. The exogenous Tb4 can be phosphorylated. At least one of the exogenous Tb4, the exogenous Sox2, and the exogenous Oct4 can be coupled with a cell membrane penetrating moiety and/or a nuclear targeting moiety, allowing them to reach to the nucleus. In addition, the induced pluripotent stem cell maintains pluripotency over at least 100 passages.